Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin (MAP)

Regional University Hospital Center (CHRU)

Status: Completed

Conditions: Meningioma

Study type: Observational

Funder types: Other

Identifiers

NCT04109404

29BRC19.0030

Details and patient eligibility

About

Investigators observe an increase risk of meningioma in patient treated by CYPROTERONE ACETATE or other form of progestin. Investigatorsdiscribe caractéristics of meningioma and treatement of the patients follow up in CHRU of Brest

Full description

Retrospective study in CHRU of brest, the investigators selected patient with history of méningioma and treated by CYPROTERONE ACETATE, CHLORMADINONE ACETATE and NOMEGESTROL ACETATE essentially The investigators excluded patient with risk factor of meningioma added at hormonal treatment exposition The investigators discribe the caractéristique of patients: age, sex, duration of the treatment, the caractéristique of the meningioma: localization, grade, hormonal receptors, treatment by surgery or radiotherapy and changing after discontinuation of treatment

Enrollment: 110 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• minimum 18 years
• medical follow up in CHRU of Brest
• treated by CYPROTERONE ACETATE and/or CHLORMADINONE ACETATE NOMEGESTROL ACETATE, PROGESTERONE , DYDROGESTERONE PROMEGESTONE , NORETHISTERONE, LEVONORGESTREL , oestroprogestogenic contraception
• meningioma after treatement by progestin or CYPROTERONE ACETATE

Exclusion criteria

• history ofbreast cancer
• history of cerebral radiotherapy
• history of neurofibromatosis
• meningioma before treatement by progestin or CYPROTERONE ACETATE
• minor patient